XML 56 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity - Inducement Plan (Details)
1 Months Ended 12 Months Ended
May 31, 2022
shares
Jan. 31, 2022
USD ($)
shares
Aug. 31, 2021
shares
Jan. 31, 2020
installment
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Jan. 09, 2014
shares
Inducement Plan                
Share-based Compensation Arrangement by Share-based Payment Award                
Expiration period       10 years        
Unrecognized compensation expense related to unvested options | $         $ 1,473,466      
Intrinsic value of options exercised | $           $ 1,944,000    
Cash proceeds from exercise of stock options | $           $ 20,790    
Period for unrecognized compensation expense related to unvested options yet has not been recognized         2 years 8 months 12 days      
Common stock shares issued           10,092    
Aggregate intrinsic value | $         $ 2,867,000      
Stock options granted         535,000      
Fair value of shares vested | $         $ 604,440 $ 73,334    
Options exercised         0   0  
Inducement Plan | Stock options vesting based on performance | Employees                
Share-based Compensation Arrangement by Share-based Payment Award                
Stock options granted         584,200 584,200    
Maximum fair value of option excluded from the unrecognized compensation expense | $         $ 825,353 $ 825,353    
Inducement Plan | Upon first anniversary of start date                
Share-based Compensation Arrangement by Share-based Payment Award                
Vesting percentage       25.00%        
Number of monthly installments | installment       36        
Period from date of termination that any vested options shall expire       90 days        
2013 Equity Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award                
Period from date of termination that any vested options shall expire         90 days      
Expiration period         10 years      
Period for unrecognized compensation expense related to unvested options yet has not been recognized         2 years      
Aggregate intrinsic value | $         $ 3,506,000      
Stock options granted         2,020,800      
Fair value of shares vested | $         $ 3,306,412 $ 5,936,641 $ 7,347,548  
Options exercised         0 0 0  
2013 Equity Incentive Plan | Stock options vesting based on performance | Employees                
Share-based Compensation Arrangement by Share-based Payment Award                
Shares available for future grants   189,600            
Maximum fair value of option excluded from the unrecognized compensation expense | $   $ 151,680            
2013 Equity Incentive Plan | Upon first anniversary of start date                
Share-based Compensation Arrangement by Share-based Payment Award                
Vesting percentage         25.00%      
2013 Equity Incentive Plan | Each month after the first anniversary                
Share-based Compensation Arrangement by Share-based Payment Award                
Vesting percentage         2.083%      
2013 Equity Incentive Plan | Vesting upon FDA Approval | Stock options vesting based on performance | Employees                
Share-based Compensation Arrangement by Share-based Payment Award                
Vesting percentage   50.00%            
2013 Equity Incentive Plan | Vesting upon First Commercial Sale | Stock options vesting based on performance | Employees                
Share-based Compensation Arrangement by Share-based Payment Award                
Vesting percentage   50.00%            
Common Stock | Inducement Plan                
Share-based Compensation Arrangement by Share-based Payment Award                
Common stock authorized       500,000        
Increase in number of shares of common stock   3,000,000 2,000,000          
Shares available for future grants         656,383      
Common Stock | 2013 Equity Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award                
Common stock authorized         9,506,767     1,000,000
Increase in number of shares of common stock 2,619,622              
Shares available for future grants         1,976,154